Aktis Oncology Raises $318 Million at $18 per Share in IPO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16h ago
0mins
Source: renaissancecapital
- Successful Fundraising: Aktis Oncology raised $318 million by offering 17.7 million shares at $18 each, reaching the high end of the $16 to $18 range, indicating strong market confidence in its potential value.
- Market Capitalization: Following this financing, Aktis commands a fully diluted market cap of $1 billion, marking a significant position in the biopharmaceutical sector and providing essential funding for future R&D and market expansion.
- Clinical Progress: Aktis is conducting a multi-site US Phase 1b trial for Ac-AKY-1189 targeting Nectin-4 expressing cancers, currently enrolling about 150 patients, with preliminary results expected in Q1 2027, which will add crucial data support to its product pipeline.
- Strategic Partnerships: Aktis's collaboration with Eli Lilly involves a $100 million share subscription, further bolstering market confidence in its radiopharmaceutical development, while the company plans to operate an internal cGMP facility by 2026 to enhance its R&D and production capabilities.
Analyst Views on AKTS
Wall Street analysts forecast AKTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 0.000
Low
Averages
High
Current: 0.000
Low
Averages
High
No data
About AKTS
ATech (Parent) Resolution Corp., formerly Akoustis Technologies, Inc., is not engaged in any business operating activity. The Company has no assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
